In 1967, Ashbaugh and associates (1) described the development of acute respiratory
failure in 12 patients with tachypnea, hypoxemia, and a loss of lung compliance who did not …

Background Preclinical studies suggest that exogenous surfactant may be of value in the
treatment of the acute respiratory distress syndrome (ARDS), and two phase 2 clinical trials …

We performed a phase I/II trial in North America of a recombinant surfactant protein C–based
surfactant (Venticute) as treatment for the acute respiratory distress syndrome. Patients …

▪ Abstract A number of conditions, such as pneumonia, trauma, or systemic sepsis arising
from the gut, may result in the acute respiratory distress syndrome (ARDS). Because of its …

Rationale: Patients with acute lung injury have impaired function of the lung surfactant
system. Prior clinical trials have shown that treatment with exogenous recombinant surfactant …

Background Studies to date have shown no survival benefit for the use of exogenous surfactant
to treat patients with the ARDS. To identify specific patient subgroups for future study, we …

Components of the airspace-lining material may contribute to the local regulation of immune
function within the lung. We report here that recombinant rat pulmonary surfactant-…

The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the
lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically …

Background Ex vivo lung perfusion (EVLP) provides opportunities to treat injured donor
lungs before transplantation. We investigated whether lung lavage, to eliminate inflammatory …

Introduction The dramatic impact of COVID-19 on humans worldwide has initiated an
extraordinary search for effective treatment approaches. One of these is the administration of …